AU1710699A - Venezuelan equine encephalitis virus vectors expressing tumor-associated antigens to induce cancer immunity - Google Patents

Venezuelan equine encephalitis virus vectors expressing tumor-associated antigens to induce cancer immunity

Info

Publication number
AU1710699A
AU1710699A AU17106/99A AU1710699A AU1710699A AU 1710699 A AU1710699 A AU 1710699A AU 17106/99 A AU17106/99 A AU 17106/99A AU 1710699 A AU1710699 A AU 1710699A AU 1710699 A AU1710699 A AU 1710699A
Authority
AU
Australia
Prior art keywords
encephalitis virus
associated antigens
virus vectors
equine encephalitis
expressing tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU17106/99A
Inventor
Paul J. Hippenmeyer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GD Searle LLC
Original Assignee
GD Searle LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GD Searle LLC filed Critical GD Searle LLC
Publication of AU1710699A publication Critical patent/AU1710699A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464484—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/464486—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU17106/99A 1997-12-18 1998-12-14 Venezuelan equine encephalitis virus vectors expressing tumor-associated antigens to induce cancer immunity Abandoned AU1710699A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6808097P 1997-12-18 1997-12-18
US60068080 1997-12-18
PCT/US1998/025725 WO1999030734A1 (en) 1997-12-18 1998-12-14 Venezuelan equine encephalitis virus vectors expressing tumor-associated antigens to induce cancer immunity

Publications (1)

Publication Number Publication Date
AU1710699A true AU1710699A (en) 1999-07-05

Family

ID=22080300

Family Applications (1)

Application Number Title Priority Date Filing Date
AU17106/99A Abandoned AU1710699A (en) 1997-12-18 1998-12-14 Venezuelan equine encephalitis virus vectors expressing tumor-associated antigens to induce cancer immunity

Country Status (4)

Country Link
EP (1) EP1039926A1 (en)
AU (1) AU1710699A (en)
CA (1) CA2309765A1 (en)
WO (1) WO1999030734A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU754320B2 (en) * 1998-04-08 2002-11-14 University Of North Carolina At Chapel Hill, The Methods and modified cells for the treatment of cancer

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
US6451592B1 (en) 1996-04-05 2002-09-17 Chiron Corporation Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
US6844188B1 (en) 1998-04-08 2005-01-18 University Of North Carolina At Chapel Hill Methods and modified cells for the treatment of cancer
US6482405B1 (en) 1998-09-15 2002-11-19 University Of Pittsburgh Of The Commonwealth System Of Higher Education In situ injection of antigen-presenting cells with genetically enhanced cytokine expression
US8647864B2 (en) 1999-04-14 2014-02-11 Novartis Ag Compositions and methods for generating an immune response utilizing alphavirus-based vector systems
AU7781000A (en) * 1999-09-23 2001-04-24 Thomas Brocker Highly efficient dendritic cell-targeted dna-vaccination
CA2410948C (en) 2000-05-31 2012-07-17 Chiron Corporation Method for the purification of alphavirus replicon particles
CA2572921C (en) 2004-07-09 2017-01-03 The University Of North Carolina At Chapel Hill Replication-competent and propagation-defective venezuelan equine encephalitis (vee) viral adjuvants
CA2597921A1 (en) 2005-02-15 2007-04-26 University Of North Carolina At Chapel Hill New live virus vaccines

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5541104A (en) * 1991-05-23 1996-07-30 Ludwig Institute For Cancer Research Monoclonal antibodies which bind to tumor rejection antigen precursor mage-1
JPH09502086A (en) * 1993-08-06 1997-03-04 サイテル コーポレイション Cloning and characterization of the complete MAGE1 gene
US5505947A (en) * 1994-05-27 1996-04-09 The University Of North Carolina At Chapel Hill Attenuating mutations in Venezuelan Equine Encephalitis virus
WO1998008947A1 (en) * 1995-12-19 1998-03-05 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Enhancement of dna immunization through the use of cytokines
WO1997024447A1 (en) * 1996-01-02 1997-07-10 Chiron Corporation Immunostimulation mediated by gene-modified dendritic cells

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU754320B2 (en) * 1998-04-08 2002-11-14 University Of North Carolina At Chapel Hill, The Methods and modified cells for the treatment of cancer

Also Published As

Publication number Publication date
WO1999030734A1 (en) 1999-06-24
EP1039926A1 (en) 2000-10-04
CA2309765A1 (en) 1999-06-24

Similar Documents

Publication Publication Date Title
AU7089600A (en) Monoclonal antibodies and vaccines against epitopes on the ebola virus glycoprotein
AU3834999A (en) Recombinant venezuelan equine encephalitis virus vaccine
AU9623898A (en) Vaccines
AU6304996A (en) Vaccines against hepatitis c
AU3107289A (en) Chimeric antibodies directed against human carcinoembryonic antigen
AU7685200A (en) Powdery inhalational preparations and process for producing the same
AU3760100A (en) Immunostimulatory nucleic acids and antigens
AU7462198A (en) Horn antenna
AU1951201A (en) Peptide antigens
AUPN999096A0 (en) Peptides, antibodies, vaccines & uses thereof
AU6080794A (en) Antibodies directed against binding-associated epitopes
AU1710699A (en) Venezuelan equine encephalitis virus vectors expressing tumor-associated antigens to induce cancer immunity
MXPA02004942A (en) Use of anti idiotypical antibodies as vaccines against cancer.
AU2948199A (en) Breast cancer antigen
AU2247095A (en) Cellular immune response-specific antigens and uses therefor
AU7471098A (en) Recombinant influenza viruses expressing tumor-associated antigens as antitum or agents
GB9804065D0 (en) Tumour associated antigen 791Tgp72
GB9620350D0 (en) Cancer vaccine
AU5632500A (en) Cancer associated antigens and uses therefor
AU5974299A (en) A polyvalent bifunctional catalyst and the process of realisation of such a catalyst
AU4553100A (en) Tumour-associated antigen
AU1288301A (en) Composite particles, derived conjugates and their conjugates with biomolecules
AU4399197A (en) Hepatitis c virus epitope
AU3930895A (en) Viral preparations, immunogens, and vaccines
AU6832200A (en) Moraxella cattarrhalis basb114 antigens and uses thereof

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase